Page 87 - 2018_10-Haematologica-web

Effects of XPO1 and FLT3 inhibition on AML
mediated regulation of microRNAs: poten- tial target for drug intervention. Curr Drug Targets. 2013;14(10):1094-1100.
16. Azmi AS, Li Y, Muqbil I, et al. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell prolif- eration and migration. Oncotarget. 2017;8(47):82144-82155.
17. Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166-4174.
18. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal- mediated nuclear protein export. Science. 1997;278(5335):141-144.
19. Etchin J, Montero J, Berezovskaya A, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML- initiating cells engrafted into immunosup- pressed NSG mice. Leukemia. 2016;30(1): 190-199.
20. Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refracto- ry acute leukemia. J Clin Oncol. 2016;34(34): 4094-4101.
21. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765- 1773.
22. Muz B, Azab F, de la Puente P, Landesman Y, Azab AK. Selinexor overcomes hypoxia- induced drug resistance in multiple myelo- ma. Transl Oncol. 2017;10(4):632-640.
23. Savona M, Garzon R, Brown P, et al. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). Blood. 2013;122(21):1440a.
24. Bhatnagar B, Klisovic RB, Walker AR, et al. A phase 1 clinical trial of selinexor in combi- nation with decitabine in patients with newly diagnosed and relapsed or refractory acute myeloid leukemia. Blood. 2016;128 (21):1651a.
25. Sweet KL, Komrokji RS, Padron E, et al. A phase I study of selinexor in combination
with daunorubicin and cytarabine in patients with newly diagnosed poor-risk acute myeloid leukemia. Blood. 2016;128 (22):4040a.
26. Fiedler W, Heuser M, Chromik J, et al. Phase II results of ara-C and idarubicin in combina- tion with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT- 330) in patients with relapsed or refractory AML. Blood. 2016;128(22):341s.
27. Garzon R, Savona M, Baz R, et al. A phase I clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24): 3165-3174.
28. Garg M, Nagata Y, Kanojia D, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015;126(22):2491-2501.
29. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260-263.
30. Zhang W, Gao C, Konopleva M, et al. Reversal of acquired drug resistance in FLT3- mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014;20(9): 2363-2374.
31. Clodi K, Kliche KO, Zhao S, et al. Cell-sur- face exposure of phosphatidylserine corre- lates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulat- ing genes. Cytometry. 2000;40(1):19-25.
32. Pajarinen J, Lin TH, Sato T, et al. Establishment of green fluorescent protein and firefly luciferase expressing mouse pri- mary macrophages for in vivo biolumines- cence Imaging. PLoS One. 2015;10(11): e0142736.
33. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
34. Kaplan E, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
35. Tabe Y, Konopleva M. Role of microenviron- ment in resistance to therapy in AML. Curr
Hematol Malig Rep. 2015;10(2):96-103.
36. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differenti- ation through suppression of C/EBPalpha
expression. Blood. 2004;103(5):1883-1890. 37. Dahl R, Walsh JC, Lancki D, et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat
Immunol. 2003;4(10):1029-1036.
38. Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood.
2012;120(20):4205-4214.
39. Schepers H, Wierenga AT, van Gosliga D,
Eggen BJ, Vellenga E, Schuringa JJ. Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self- renewal and partially restores myelopoiesis. Blood. 2007;110(4):1317-1325.
40. Yoon K, Smart RC. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol. 2004;24(24):10650-10660.
41. Meyer M, Rubsamen D, Slany R, et al. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One. 2009;4(11):e7768.
42. Wheadon H, Roberts PJ, Watts MJ, Linch DC. Changes in signal transduction down- stream from the granulocyte-macrophage colony-stimulating factor receptor during differentiation of primary hemopoietic cells. Exp Hematol. 1999;27(6):1077-1086.
43. Bunting KD, Bradley HL, Hawley TS, Moriggl R, Sorrentino BP, Ihle JN. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 2002;99(2):479-487.
44. Minami M, Inoue M, Wei S, et al. STAT3 activation is a critical step in gp130-mediat- ed terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA. 1996;93(9):3963-3966.
45. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in mono- cytic and granulocytic differentiation of myeloid cell lines. Leukemia. 2002;16(4): 683-692.
haematologica | 2018; 103(10)
1653